Mevalonate pathway is a highly conserved pathway that produces isoprenoids and cholesterol, and it is often increased in cancer cells. Cholesterol, upstream metabolites including isoprenoids and cholesterol derivatives such as oxysterols modulate cell proliferation, motility, stemness and drug resistance. Moreover, when produced by cancer cells or immune infiltrating cells, they modulate the activity of immune populations of the tumor microenvironment. In this review, we will focus on the recent findings demonstrating that cholesterol derivatives may regulate tumor immune recognition or immune escape, playing a critical role in the immune surveillance. Since the mevalonate pathway is druggable, a deeper knowledge of the metabolic cross talks existing between the mevalonate pathway of cancer cells and immune cells may help to identify novel agents targeting cholesterol metabolism, able to boost the anti-tumor activity of the immune populations.

Cholesterol metabolism: At the cross road between cancer cells and immune environment

Kopecka J.;Godel M.;Riganti C.
2020

Abstract

Mevalonate pathway is a highly conserved pathway that produces isoprenoids and cholesterol, and it is often increased in cancer cells. Cholesterol, upstream metabolites including isoprenoids and cholesterol derivatives such as oxysterols modulate cell proliferation, motility, stemness and drug resistance. Moreover, when produced by cancer cells or immune infiltrating cells, they modulate the activity of immune populations of the tumor microenvironment. In this review, we will focus on the recent findings demonstrating that cholesterol derivatives may regulate tumor immune recognition or immune escape, playing a critical role in the immune surveillance. Since the mevalonate pathway is druggable, a deeper knowledge of the metabolic cross talks existing between the mevalonate pathway of cancer cells and immune cells may help to identify novel agents targeting cholesterol metabolism, able to boost the anti-tumor activity of the immune populations.
129
105876
105880
Cancer; Cholesterol; Immune modulation
Kopecka J.; Godel M.; Riganti C.
File in questo prodotto:
File Dimensione Formato  
Kopecka, IJBCB 2020.pdf

Accesso riservato

Descrizione: Kopecka, IJBCB 2020
Tipo di file: PDF EDITORIALE
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Kopecka_IJBCB_Manuscript_R1.docx

Accesso riservato

Descrizione: Kopecka, preparint 2020 IJBCB
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 45.02 kB
Formato Microsoft Word XML
45.02 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
Kopecka_IJBCB_Manuscript_R1.pdf

Accesso aperto

Descrizione: Kopecka, preparint 2020 IJBCB
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 182.25 kB
Formato Adobe PDF
182.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1765851
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact